Report Detail
Global Myelodysplastic Syndrome (MDS) Therapeutics Market Insights, Forecast to 2025
- RnM2883569 |
- 20 February, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Machinery & Equipment
The Myelodysplastic Syndrome (MDS) Therapeutics market was valued at Million US$ in 2018 and is projected to reach Million US$ by 2025, at a CAGR of during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Myelodysplastic Syndrome (MDS) Therapeutics.
This report presents the worldwide Myelodysplastic Syndrome (MDS) Therapeutics market size (value, production and consumption), splits the breakdown (data status 2014-2019 and forecast to 2025), by manufacturers, region, type and application.
This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
The following manufacturers are covered in this report:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd.
Sandoz Inc.
Dr Reddys Laboratories Limited
Pharmascience Inc.
Accord Healthcare Ltd
Mylan N.V.
Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Others
Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Application
In-Patient
Out-Patient
Myelodysplastic Syndrome (MDS) Therapeutics Production by Region
United States
Europe
China
Japan
Other Regions
Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Russia
Rest of Europe
Central & South America
Brazil
Rest of South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
Rest of Middle East & Africa
The study objectives are:
To analyze and research the global Myelodysplastic Syndrome (MDS) Therapeutics status and future forecast，involving, production, revenue, consumption, historical and forecast.
To present the key Myelodysplastic Syndrome (MDS) Therapeutics manufacturers, production, revenue, market share, and recent development.
To split the breakdown data by regions, type, manufacturers and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Therapeutics :
History Year: 2014 - 2018
Base Year: 2018
Estimated Year: 2019
Forecast Year: 2019 - 2025
This report includes the estimation of market size for value (million USD) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Myelodysplastic Syndrome (MDS) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Myelodysplastic Syndrome (MDS) Therapeutics Product
- 1.2 Key Market Segments in This Study
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type
- 1.4.2 Azacitidine
- 1.4.3 Lenalidomide
- 1.4.4 Decitabine
- 1.4.5 Deferasirox
- 1.4.6 Others
- 1.5 Market by Application
- 1.5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Application
- 1.5.2 In-Patient
- 1.5.3 Out-Patient
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size
- 2.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue 2014-2025
- 2.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Production 2014-2025
- 2.2 Myelodysplastic Syndrome (MDS) Therapeutics Growth Rate (CAGR) 2019-2025
- 2.3 Analysis of Competitive Landscape
- 2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
- 2.3.2 Key Myelodysplastic Syndrome (MDS) Therapeutics Manufacturers
- 2.3.2.1 Myelodysplastic Syndrome (MDS) Therapeutics Manufacturing Base Distribution, Headquarters
- 2.3.2.2 Manufacturers Myelodysplastic Syndrome (MDS) Therapeutics Product Offered
- 2.3.2.3 Date of Manufacturers Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
- 2.4 Key Trends for Myelodysplastic Syndrome (MDS) Therapeutics Markets & Products
3 Market Size by Manufacturers
- 3.1 Myelodysplastic Syndrome (MDS) Therapeutics Production by Manufacturers
- 3.1.1 Myelodysplastic Syndrome (MDS) Therapeutics Production by Manufacturers
- 3.1.2 Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share by Manufacturers
- 3.2 Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Manufacturers
- 3.2.1 Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Myelodysplastic Syndrome (MDS) Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Myelodysplastic Syndrome (MDS) Therapeutics Price by Manufacturers
- 3.4 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome (MDS) Therapeutics Production by Regions
- 4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production by Regions
- 4.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share by Regions
- 4.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Regions
- 4.2 United States
- 4.2.1 United States Myelodysplastic Syndrome (MDS) Therapeutics Production
- 4.2.2 United States Myelodysplastic Syndrome (MDS) Therapeutics Revenue
- 4.2.3 Key Players in United States
- 4.2.4 United States Myelodysplastic Syndrome (MDS) Therapeutics Import & Export
- 4.3 Europe
- 4.3.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Production
- 4.3.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue
- 4.3.3 Key Players in Europe
- 4.3.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Import & Export
- 4.4 China
- 4.4.1 China Myelodysplastic Syndrome (MDS) Therapeutics Production
- 4.4.2 China Myelodysplastic Syndrome (MDS) Therapeutics Revenue
- 4.4.3 Key Players in China
- 4.4.4 China Myelodysplastic Syndrome (MDS) Therapeutics Import & Export
- 4.5 Japan
- 4.5.1 Japan Myelodysplastic Syndrome (MDS) Therapeutics Production
- 4.5.2 Japan Myelodysplastic Syndrome (MDS) Therapeutics Revenue
- 4.5.3 Key Players in Japan
- 4.5.4 Japan Myelodysplastic Syndrome (MDS) Therapeutics Import & Export
- 4.6 Other Regions
- 4.6.1 South Korea
- 4.6.2 India
- 4.6.3 Southeast Asia
5 Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Regions
- 5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Regions
- 5.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Regions
- 5.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Market Share by Regions
- 5.2 North America
- 5.2.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 5.2.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Countries
- 5.2.3 United States
- 5.2.4 Canada
- 5.2.5 Mexico
- 5.3 Europe
- 5.3.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 5.3.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Countries
- 5.3.3 Germany
- 5.3.4 France
- 5.3.5 UK
- 5.3.6 Italy
- 5.3.7 Russia
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 5.4.2 Asia Pacific Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Countries
- 5.4.3 China
- 5.4.4 Japan
- 5.4.5 South Korea
- 5.4.6 India
- 5.4.7 Australia
- 5.4.8 Indonesia
- 5.4.9 Thailand
- 5.4.10 Malaysia
- 5.4.11 Philippines
- 5.4.12 Vietnam
- 5.5 Central & South America
- 5.5.1 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 5.5.2 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Country
- 5.5.3 Brazil
- 5.6 Middle East and Africa
- 5.6.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 5.6.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Countries
- 5.6.3 GCC Countries
- 5.6.4 Egypt
- 5.6.5 South Africa
6 Market Size by Type
- 6.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production by Type
- 6.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Type
- 6.3 Myelodysplastic Syndrome (MDS) Therapeutics Price by Type
7 Market Size by Application
- 7.1 Overview
- 7.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Dada by Application
- 7.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
- 7.2.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Market Share by Application (2014-2019)
8 Manufacturers Profiles
- 8.1 Novartis AG
- 8.1.1 Novartis AG Company Details
- 8.1.2 Company Overview
- 8.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.1.4 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.1.5 Novartis AG Recent Development
- 8.2 Celgene Corporation
- 8.2.1 Celgene Corporation Company Details
- 8.2.2 Company Overview
- 8.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.2.4 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.2.5 Celgene Corporation Recent Development
- 8.3 Otsuka Pharmaceutical Co., Ltd.
- 8.3.1 Otsuka Pharmaceutical Co., Ltd. Company Details
- 8.3.2 Company Overview
- 8.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.3.4 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.3.5 Otsuka Pharmaceutical Co., Ltd. Recent Development
- 8.4 Sandoz Inc.
- 8.4.1 Sandoz Inc. Company Details
- 8.4.2 Company Overview
- 8.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.4.4 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.4.5 Sandoz Inc. Recent Development
- 8.5 Dr Reddys Laboratories Limited
- 8.5.1 Dr Reddys Laboratories Limited Company Details
- 8.5.2 Company Overview
- 8.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.5.4 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.5.5 Dr Reddys Laboratories Limited Recent Development
- 8.6 Pharmascience Inc.
- 8.6.1 Pharmascience Inc. Company Details
- 8.6.2 Company Overview
- 8.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.6.4 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.6.5 Pharmascience Inc. Recent Development
- 8.7 Accord Healthcare Ltd
- 8.7.1 Accord Healthcare Ltd Company Details
- 8.7.2 Company Overview
- 8.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.7.4 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.7.5 Accord Healthcare Ltd Recent Development
- 8.8 Mylan N.V.
- 8.8.1 Mylan N.V. Company Details
- 8.8.2 Company Overview
- 8.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production Revenue and Gross Margin (2014-2019)
- 8.8.4 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Product Description
- 8.8.5 Mylan N.V. Recent Development
9 Production Forecasts
- 9.1 Myelodysplastic Syndrome (MDS) Therapeutics Production and Revenue Forecast
- 9.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production Forecast 2019-2025
- 9.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Forecast 2019-2025
- 9.2 Myelodysplastic Syndrome (MDS) Therapeutics Production and Revenue Forecast by Regions
- 9.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Forecast by Regions
- 9.2.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Production Forecast by Regions
- 9.3 Myelodysplastic Syndrome (MDS) Therapeutics Key Producers Forecast
- 9.3.1 United States
- 9.3.2 Europe
- 9.3.3 China
- 9.3.4 Japan
- 9.4 Forecast by Type
- 9.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production Forecast by Type
- 9.4.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Forecast by Type
10 Consumption Forecast
- 10.1 Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Application
- 10.2 Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions
- 10.3 North America Market Consumption Forecast
- 10.3.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions 2019-2025
- 10.3.2 United States
- 10.3.3 Canada
- 10.3.4 Mexico
- 10.4 Europe Market Consumption Forecast
- 10.4.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions 2019-2025
- 10.4.2 Germany
- 10.4.3 France
- 10.4.4 UK
- 10.4.5 Italy
- 10.4.6 Russia
- 10.5 Asia Pacific Market Consumption Forecast
- 10.5.1 Asia Pacific Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions 2019-2025
- 10.5.2 China
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 India
- 10.5.6 Australia
- 10.5.7 Indonesia
- 10.5.8 Thailand
- 10.5.9 Malaysia
- 10.5.10 Philippines
- 10.5.11 Vietnam
- 10.6 Central & South America Market Consumption Forecast
- 10.6.1 Central & South America Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions 2019-2025
- 10.6.2 Brazil
- 10.7 Middle East and Africa Market Consumption Forecast
- 10.7.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Therapeutics Consumption Forecast by Regions 2019-2025
- 10.7.2 GCC Countries
- 10.7.3 Egypt
- 10.7.4 South Africa
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Myelodysplastic Syndrome (MDS) Therapeutics Sales Channels
- 11.2.2 Myelodysplastic Syndrome (MDS) Therapeutics Distributors
- 11.3 Myelodysplastic Syndrome (MDS) Therapeutics Customers
12 Market Opportunities & Challenges, Risks and Influences Factors Analysis
- 12.1 Market Opportunities and Drivers
- 12.2 Market Challenges
- 12.3 Market Risks/Restraints
13 Key Findings in the Global Myelodysplastic Syndrome (MDS) Therapeutics Study
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Myelodysplastic Syndrome (MDS) Therapeutics . Industry analysis & Market Report on Myelodysplastic Syndrome (MDS) Therapeutics is a syndicated market report, published as Global Myelodysplastic Syndrome (MDS) Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Myelodysplastic Syndrome (MDS) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
